High risk of a large measles outbreak despite 30 years of measles vaccination in The Netherlands

Epidemiology and Infection

Volumn 142, Issue 5, 2014, Pages 1100-1108

  Mollema, L ^a   Smits, G P ^a   Berbers, G A ^a   Van Der Klis, F R ^a   Van Binnendijk, R S ^a   De Melker, H E ^a   Hahne S J M ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Infectious disease epidemiology; measles (rubeola); MMR vaccination; serology; vaccine preventable diseases

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; MEASLES ANTIBODY;

ADULT; ARTICLE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DUTCH; EPIDEMIC; ETHNIC GROUP; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNOASSAY; INFANT; INFECTION RISK; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MEASLES; MEASLES VACCINATION; NETHERLANDS; POPULATION RESEARCH; POPULATION SIZE; PRESCHOOL CHILD; RELIGION; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SEROEPIDEMIOLOGY; SEROPREVALENCE; AGE DISTRIBUTION; DISEASE PREDISPOSITION; HIGH RISK POPULATION; IMMUNE RESPONSE; PROTESTANT; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, BACTERIAL; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DISEASE OUTBREAKS; FEMALE; HUMANS; INFANT; MALE; MEASLES; MEASLES-MUMPS-RUBELLA VACCINE; MIDDLE AGED; NETHERLANDS; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; VACCINATION; YOUNG ADULT;

EID: 84897032507     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268813001532     Document Type: Article

References (41)

1. Simons E, et al. Assessment of the 2010 global measles mortality reduction goal: Results from a model of surveillance data. Lancet 2012; 379: 2173-2178
2. World Health Organization. Strategic plan for measles and congenital rubella infection in the WHO European Region. Copenhagen, Denmark: WHO Regional Office for Europe, 2003
3. Khetsuriani N, et al. Supplementary immunization activities to achieve measles elimination: Experience of the European region. Journal Infectious Diseases 2011; 204 (Suppl. 1): 343-352
4. European Centre for Disease Prevention and Control (ECDC). European monthly measles monitoring (EMMO). Issue 10. Stockholm: ECDC, 2012
5. Muscat M. Who gets measles in Europe? Journal Infectious Diseases 2011; 204 (Suppl. 1): 353-365
6. Van Lier EA, et al. Vaccination coverage national immunization program the Netherlands [in Dutch]. Bilthoven, The Netherlands: National Institute for Public Health and the Environment, 2012. Report 201001001/2012
7. Ruijs WL, et al. Religious subgroups influencing vaccination coverage in the Dutch Bible belt: An ecological study. BMC Public Health 2011; 11: 102
8. Bijkerk H, Bilkert-Mooiman MA, Houtters HJ. The immunization status of patients registered with measles during the 1987-88 epidemic [in Dutch]. Nederlands Tijdschrift voor Geneeskunde 1989; 133: 29-32
9. Van der Zwan CW, et al. Measles in the Netherlands: Epidemiology and the effect of vaccination [in Dutch]. Nederlands Tijdschrift voor Geneeskunde 1994; 138: 2390-2395
10. Wallinga J, van den Hof S. Measles epidemiology in the Netherlands: An exploratory analysis of notification [in Dutch]. Nederlands Tijdschrift voor Geneeskunde 2000; 144: 171-174
11. Van den Hof S, Conyn-van Spaendonck MAE, van Steenbergen JE. Measles epidemic in the Netherlands, 1999-2000. Journal Infectious Diseases 2002; 186: 1483-1486
12. Hahné S, et al. Measles outbreak, the Netherlands, 2008. Emerging Infectious Diseases 2010; 16: 567-568
13. Van den Hof S, et al. Sero-epidemiologic study of measles antibodies in the Netherlands, a crosssectional study in a national sample and in municipalities with low vaccine coverage. Vaccine 2000; 18: 931-940
14. De Melker HE, Conyn-van Spaendonck MA. Immunosurveillance and the evaluation of national immunization programmes: A population-based approach. Epidemiology and Infection 1998; 121: 637-643
15. Van der Klis FRM, et al. Second national serum bank for population-based seroprevalence studies in the Netherlands. Netherlands Journal of Medicine 2009; 67: 301-308
16. Smits GP, et al. Development of a bead-based multiplex immunoassay for the simultaneously quantitative detection of IgG serum antibodies against measles, mumps, rubella and varicella zoster. Clinical Vaccine Immunology 2012; 19: 396-400
17. Chen RT, et al. Measles antibody: Reevaluation of protective titers. Journal Infectious Diseases 1990; 162: 1036-1042
18. The R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2011
19. Statistics Netherlands. Population on 1 January 2007 http://www.cbs.nl). Accessed 1 January 2009
20. Statistics Netherlands. Degree of urbaniziation per municipality (http://www.cbs.nl). Accessed 1 October 2007
21. Ruijs WLM, et al. Measuring vaccination coverage in a hard to reach minority. European Journal of Public Health 2012; 22: 359-364
22. Bickel PJ, Doksum KA. Basic heuristics of estimation. In: Bickel PJ and Doksum KA, eds. Mathematical Statistics. Basic Ideas and Selected Topics. London: Prentice-Hall, 2001, pp. 101
23. Gay NJ. The theory of measles elimination: Implications for the design of elimination strategies. Journal Infectious Diseases 2004; 189 (Suppl. 1): 27-35
24. Wallinga J, Heijne JCM, Kretzschmar M. A measles epidemic threshold in a highly vaccinated population. PLoS Medicine 2005; 2: E316
25. Bartlett MS. The critical community size for measles in the United States. Journal of the Royal Statistical Society. Series A (General) 1960; 123: 37-44
26. Ruijs WL, et al. How orthodox protestant parents decide on the vaccination of their children: A qualitative study. BMC Public Health 2012; 12: 408
27. Ruijs WL, et al. How healthcare professionals respond to parents with religious objections to vaccination: A qualitative study. BMC Health Services Research 2012; 12: 231
28. Van 't Klooster TM, de Melker HE. The national immunisation programme in the Netherlands: Developments 2012. Bilthoven, The Netherlands: National Institute for Public Health and the Environment, 2012. Report 201001002/2012
29. Van den Hof S, et al. Options for improvement of the Dutch measles vaccination schedule. Vaccine 2003; 21: 721-724
30. Lee MS, et al. Measles seroepidemiology and decay rate of vaccine-induced measles IgG titers in Taiwan, 1995-1997. Vaccine 2007; 19: 4644-4651
31. Wetsteyn JCFM, et al. Measles outbreak at the intensive care [in Dutch]. Nederlands Tijdschrift voor Geneeskunde 2008; 152: 2032-2036
32. Van den Hoek A, et al. Two cases of mild IgM-negative measles in previously vaccinated adults, the Netherlands, April and July 2011. Eurosurveillance 2011; 16: Pii=20028
33. Poethko-Müller C, Mankertz A. Sero-epidemiology of measles-specific IgG antibodies and predictive factors for low or missing titers in a German population-based cross-sectional study in children and adolescents (KiGGS). Vaccine 2011; 29: 7949-7959
34. Christenson B, Böttiger M. Measles antibody: Comparison of long-Term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus. Vaccine 1994; 12: 129-133
35. Amela C, Pachón I, de Ory F. Evaluation of measles, mumps and rubella immunisation programme in Spain by using a sero-epidemiological survey. European Journal of Epidemiology 2003; 18: 71-79
36. Mossong J, Putz L, Schneider F. Seroprevalence of measles, mumps and rubella antibodies in Luxembourg: Results from a national cross-sectional study. Epidemiology and Infection 2003; 132: 11-18
37. Davidkin I, et al. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: A 20-year follow-up. Journal of Infectious Diseases 2008; 197: 950-956
38. Rota MC, et al. Measles serological survey in the Italian population: Interpretation of results using a mixture model. Vaccine 2008; 26: 4403-4409
39. Theeten H, et al. Are we hitting immunity targets? The 2006 age-specific seroprevalence of measles, mumps, rubella, diphtheria and tetanus in Belgium. Epidemiology and Infection 2011; 139: 494-504
40. Parker RA, Erdman DD, Anderson LJ. Use of mixture models in determining laboratory criterion for identification of seropositive individuals: Application to parvovirus B19 serology. Journal of Virological Methods 1990; 27: 135-144
41. Vyse AJ, et al. Interpreting serological surveys using mixture models: The seroepidemiology of measles, mumps and rubella in England and Wales at the beginning of the 21st century. Epidemiology and Infection 2006; 134: 1303-1312.